DMCRN-02-001: DM1 における小児エンドポイントの評価 (ASPIRE-DM1)
DM1 における小児エンドポイントの評価 (ASPIRE-DM1)
The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic dystrophy type 1 and develop biomarkers for the condition.
調査の概要
状態
詳細な説明
Myotonic dystrophy type-1 (DM1) is an autosomal dominant disorder caused by a toxic CTG repeat expansion in the 3'UTR of the DMPK gene. DM1 is the most common adult-onset muscular dystrophy, with an overall prevalence of 1:8000. In approximately 10-20% of individuals with DM1, the onset of symptoms occurs at birth, which is known as congenital myotonic dystrophy (CDM).
Previous studies have enrolled a very limited number of children with CDM.
The rationale for this study is to include a larger population of patients with CDM in order to determine developmental milestones, measures of physical and cognitive function and quality of life, and correlate functional outcome measures with potential biomarkers in CDM .
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Ruby Langeslay
- 電話番号:804-828-8481
- メール:ruby.langeslay@vcuhealth.org
研究連絡先のバックアップ
- 名前:Jennifer Raymond
- 電話番号:804-828-6318
- メール:jennifer.raymond@vcuhealth.org
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90095
- 募集
- University of California, Los Angeles
-
コンタクト:
- Merve Kaleli
- メール:MKaleli@mednet.ucla.edu
-
主任研究者:
- Perry Shieh, MD, PhD
-
コンタクト:
- Dennis Fernando
- 電話番号:310-825-3264
- メール:DeFernando@mednet.ucla.edu
-
-
Kansas
-
Fairway、Kansas、アメリカ、66205
- 募集
- University of Kansas Medical Center
-
主任研究者:
- Jeffrey Statland, MD
-
コンタクト:
- Michaela Walker
- メール:mwalker20@kumc.edu
-
コンタクト:
- Cassidy Nelson
- メール:cnelson15@kumc.edu
-
-
New York
-
Rochester、New York、アメリカ、14642
- 募集
- University of Rochester Medical Center
-
コンタクト:
- Jim Hilbert
- メール:james_hilbert@urmc.rochester.edu
-
コンタクト:
- Jeanne Dekdebrun
- メール:jeanne_dekdebrun@urmc.rochester.edu
-
主任研究者:
- Bohoon Lee, MD
-
-
Virginia
-
Richmond、Virginia、アメリカ、23298
- 募集
- Virginia Commonwealth University
-
コンタクト:
- Shantel Kyles
- メール:shantel.brown@vcuhealth.org
-
主任研究者:
- Nicholas E. Johnson, MD
-
コンタクト:
- Jodie Howell
- メール:jodie.howell@vcuhealth.org
-
-
-
-
-
Milan、イタリア、20162
- 募集
- Centro Clinico NeMO
-
コンタクト:
- Michela Nani
- メール:michela.nani@centrocliniconemo.it
-
コンタクト:
- Luca Mauro
- メール:luca.mauro@centrocliniconemo.it
-
主任研究者:
- Valeria Sansone, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
30 children with CDM
説明
Inclusion Criteria:
- Age neonate to 3 years 11 months at enrollment.
- A diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500).
- Guardian is willing and able to sign consent and follow study procedures
Exclusion Criteria:
- Any other non-DM1 illness that would interfere with the ability or results of the study in the opinion of the site investigator
- Significant trauma within one month
- Internal metal or devices (exclusion for DEXA component)
- History of bleeding disorder or platelet count <50,000
- History of reaction to local anesthetic
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Congenital Myotonic Dystrophy (CDM)
CDM group includes those aged neonate to 3 years, 11 months at enrollment. Individuals must have a diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500). |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To evaluate motor milestone attainment in individuals with CDM and ChDM and compare to typically developing children
時間枠:Through study completion at 18 months
|
Milestone Assessment using Peabody definitions: This survey would ask parents to assess the age of motor milestones in days, months of infant age. Birth history, including prematurity, ventilatory status, and feeding problems would also be collected on the CRF. Feeding and ventilatory support, as well as height and weight will be collected at each study visit. |
Through study completion at 18 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Dysarthria Assessment
時間枠:Through study completion at 18 months
|
A blinded, standardized video assessment tabulating language milestones by a trained rater will be conducted at each visit. |
Through study completion at 18 months
|
|
Vineland
時間枠:Through study completion at 18 months
|
The Vineland will be administered by an interviewer to ensure standardized intake of data. This assessment will capture the adaptive function, including gross motor and fine motor, as reported by the parent proxy. |
Through study completion at 18 months
|
|
CCMDHI
時間枠:Through study completion at 18 months
|
The congenital and childhood myotonic dystrophy health index is a disease specific patient or proxy reported outcome measure specific to these conditions. The current study will utilize the proxy version. |
Through study completion at 18 months
|
|
Domain Delta
時間枠:Through study completion at 18 months
|
This assessment asks parents for global impression of change related to the baseline visit and will be used as an anchoring measure for the statistical analyses. |
Through study completion at 18 months
|
|
Gross Motor Function Measure (GMFM-88)
時間枠:Through study completion 18 months
|
The GMFM assesses functional abilities like lying/rolling, sitting, crawling/kneeling, standing, and walking, running, and jumping. |
Through study completion 18 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Correlate the functional outcome measures with potential biomarkers in CDM.
時間枠:Baseline
|
Fine needle muscle biopsy:On the baseline visit, a fine needle aspirate will be performed. Biopsy will only be peformed once to minimize the risk. The procedure will be performed with local anesthesia (1% lidocaine without epinephrine and free of preservatives) of the vastus lateralis. Following lidocaine injection, a fine needle will be used to aspirate the quadriceps muscle to obtain a total of one aspirate. The aspirate will be flash frozen in liquid nitrogen. A similar procedure has been performed on adults with DM1, and the average biopsy yields sufficient tissue for RNA-Seq analysis. |
Baseline
|
|
Blood Sampling
時間枠:Baseline, month 12, month 18
|
DNA and RNA samples will be processed by Virginia Commonwealth University. |
Baseline, month 12, month 18
|
|
Muscle mass, DEXA
時間枠:Baseline, month 12, month 18
|
Lean muscle mass will be evaluated using serial DEXA scans as an exploratory endpoint. All sites will use a Hologic DEXA scanner. Investigators will evaluate whole body lean mass, left and right arm lean mass, and left and right leg lean mass. Particularly early in childhood, investigators would expect rapid changes in lean muscle mass. If there were a divergence between controls and subjects with CDM, this would provide evidence that CDM is a disorder of muscle maturity, as well as provide a potential biomarker. |
Baseline, month 12, month 18
|
|
World Health Organization (WHO) Motor Milestones
時間枠:Through study completion at 18 months
|
The WHO Motor Milestones is a set of 6 standardized motor milestones that include 1) Sitting without support, 2) Standing with assistance, 3) Hands-&-knees crawling, 4) Walking with assistance, 5) Standing alone, and 6) Walking alone. |
Through study completion at 18 months
|
協力者と研究者
捜査官
- 主任研究者:Nicholas E. Johnson, MD、Virginia Commonwealth University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- HM20023386
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。